CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins84% CONFIDENCEOverall confidence: 84%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
The FDA[1] press announcement and CNBC[3], BioSpace and HCPLive[2] coverage give 8 November 2023.On 8 November 2023 the US FDA approved Zepbound (tirzepatide, once weekly) for chronic weight management, with 18% average weight loss at 15 mg over 72 weeks, setting up the Wegovy versus Zepbound rivalry.
1.00